Journal: Materials Today Bio
Article Title: Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy
doi: 10.1016/j.mtbio.2026.102877
Figure Lengend Snippet: In vivo biodistribution and in vitro cellular uptake of iRGD-NPs (si-FN1). Note: (A) Schematic of the in vivo biodistribution testing experiment of iRGD-NPs (si-FN1) in nude mice with subcutaneous xenografts; (B) IVIS images of xenograft-bearing mice at 0, 4, 8, 12, and 24 h after injection with Cy5.5-labeled iRGD-NPs (si-FN1) and NPs (si-FN1); (C) Representative IVIS images of xenograft tissues and various organs from mice 24 h after injection with Cy5.5-labeled iRGD-NPs (si-FN1) and NPs (si-FN1), ∗ indicates p < 0.05; (D) Schematic of the in vitro cellular uptake experiment for iRGD-NPs (si-FN1); (E-F) Immunofluorescence staining (E) and FCM (F) assessing the uptake of iRGD-NPs (si-FN1) by GBC-SD/GEM and NOZ/GEM cells, Scale bars = 25 μm; (G) 3D tumor spheroid model assessing the tumor-penetration capability conferred by iRGD modification (Scale bars = 500 μm). experiments repeated three times. Each group consists of 3 nude mice.
Article Snippet: Cy5.5 (5 mg/mL; HY-D0924, MCE, USA) was used for labeling, and siRNA dose was 1 nmol per mouse.
Techniques: In Vivo, In Vitro, Injection, Labeling, Immunofluorescence, Staining, Modification